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1. INTRODUCTION {#ctm214-sec-0040}
===============

For the past two decades, platinum‐based chemotherapy has been the standard‐of‐care, first‐line (1L) treatment for patients with advanced non‐small‐cell lung carcinoma (NSCLC) lacking targetable driver alterations. However, chemotherapy has provided only moderate benefit, with moderate‐to‐severe toxicities.[^1^](#ctm214-bib-0001){ref-type="ref"} There exists a great unmet need for more efficacious and tolerable therapy for advanced NSCLC.

Recently, substantial progress has been made in the 1L immunotherapy of advanced NSCLC. These include monotherapy blockade of programmed cell death 1 (PD‐1) in patients with programmed cell death ligand 1 (PD‐L1) tumor proportion score (TPS) of 50% or greater,[^2^](#ctm214-bib-0002){ref-type="ref"} or combination with anti‐PD‐(L)1 antibody plus chemotherapy, irrespective of tumor PD‐L1 expression. The KEYNOTE‐042 study further showed that pembrolizumab (PEM) monotherapy provided longer duration of survival than chemotherapy in patients with PD‐L1 TPS of ≥1%.[^3^](#ctm214-bib-0003){ref-type="ref"} Still, only a minority of patients obtain long‐term survival. Attempts have been made in simultaneous inhibition of immune checkpoints with complementary mechanisms of action to further improve efficacy. Accordingly, the CheckMate 227 study demonstrated survival improvement with dual inhibition of PD‐1 (nivolumab) and cytotoxic T lymphocyte antigen 4 (CTLA‐4) (ipilimumab) in patients with advanced NSCLC and PD‐L1 TPS of ≥1%, as compared with chemotherapy.[^4^](#ctm214-bib-0004){ref-type="ref"} Thus, both nivolumab plus ipilimumab (N‐I) and PEM monotherapy were recommended as chemotherapy‐free 1L treatment for PD‐L1‐positive NSCLC by the recently published National Comprehensive Cancer Network Clinical Practice Guidelines.[^5^](#ctm214-bib-0005){ref-type="ref"} However, no direct comparison data exist between these two regimens to be able to make informed patient selection, treatment decisions, and guideline recommendations.

As such, we performed this indirect comparison of efficacy and safety outcomes between N‐I and PEM in advanced NSCLC with established approaches.[^6^](#ctm214-bib-0006){ref-type="ref"}

2. METHODS {#ctm214-sec-0050}
==========

2.1. Study eligibility {#ctm214-sec-0060}
----------------------

Pubmed, Embase, and the Cochrane Center Register were searched for studies indexed from inception to October 8, 2019 by a professional librarian. We used both subject headings and text‐word terms for "pembrolizumab," "nivolumab," "ipilimumab," "non‐small‐cell lung cancer," and "randomized controlled trial." A full search strategy is shown in Supporting Information Methods. We also reviewed the major oncology conference proceedings. Study selection was conducted by two investigators independently, with discrepancy solved by consensus. Only English language publications were considered.

2.2. Data extraction {#ctm214-sec-0070}
--------------------

The outcomes of this combined analysis included overall survival (OS), progression‐free survival (PFS), objective response rate (ORR), and treatment‐related adverse events (TRAEs). We derived the hazard ratios (HRs) and its 95% confidence intervals (CIs) for OS and PFS, and the dichotomous data for ORR and TRAEs.

2.3. Data analyses {#ctm214-sec-0080}
------------------

We calculated the pooled HRs, 95% Cis, and *P*‐values for OS and PFS using inverse‐variance‐weighted method. Pooled relative risks (RRs), 95% Cis, and *P*‐values for ORR and TRAEs were computed using the Mantel Haenszel method with a fixed‐effect model. The adjusted indirect comparison was performed on arm A (N‐I) versus arm B (PEM), linked by arm C (chemotherapy) using the frequentist methods with the following formula[^7^](#ctm214-bib-0007){ref-type="ref"}: log*HR* ~AB~ = log *HR* ~AC~˗log *HR* ~BC~, and its standard error (SE) for the log *HR* was $SE\mspace{6mu}\mspace{6mu}{({\log HR{AB}})} = \sqrt{SE{({\log HR{AC}})}^{2} + SE{({\log HR{BC}})}^{2}}$. RR was evaluated similarly using this formula.

All statistical analyses were conducted using STATA (version 12.0). A two‐sided *P* of \<.05 defined statistical significance.

3. RESULTS {#ctm214-sec-0090}
==========

3.1. Characteristics of the eligible studies {#ctm214-sec-0100}
--------------------------------------------

Three studies including 2372 patients fulfilled the predefined inclusion criteria. Detailed study selection process is presented in Figure [1](#ctm214-fig-0001){ref-type="fig"}. Risk of bias was assessed according to the Cochrane collaboration\'s tool (Supporting Information Table 1) and the only source of bias was the absence of data regarding immune‐related adverse events in CheckMate 227.

![Flow diagram of trial selection](CTM2-10-107-g001){#ctm214-fig-0001}

The main characteristics of the included studies are shown in Table [1](#ctm214-tbl-0001){ref-type="table"}. One study compared N‐I with chemotherapy (CheckMate 227 part 1a). The other two studies compared PEM with chemotherapy (KEYNOTE‐024 and KEYNOTE‐042). The median follow‐up periods were 29.3, 25.2, and 12.8 months, respectively. Of the 2372 patients included, 396 were from N‐I group, 1371 from chemotherapy group, and 791 from PEM group.

###### 

Baseline characteristics and outcomes of included trials

  Items                                                                CheckMate 227                                     KEYNOTE‐024                                            KEYNOTE‐042                                                                                                                                                      
  -------------------------------------------------------------------- ------------------------------------------------- ------------------------------------------------------ ------------------------------------------------- ------------------------------------------------------------ ------------------------------------------------- ------------------------------------------------------
  All eligible patients                                                396                                               397                                                    154                                               151                                                          637                                               637
  Median age (y)                                                       64.0                                              64.0                                                   64.5                                              66.0                                                         63.0                                              63.0
  Male sex (%)                                                         64.4                                              65.5                                                   59.7                                              62.9                                                         70.6                                              71.0
  Region (%)                                                                                                                                                                                                                                                                                                                                     
  East‐Asia                                                            20.5                                              20.4                                                   13.6                                              12.6                                                         29.0                                              29.0
  Non‐East Asia                                                        79.6                                              79.6                                                   86.4                                              87.4                                                         71.0                                              71.0
  ECOG[^a^](#ctm214-tbl1-note-0002){ref-type="fn"} score (%)                                                                                                                                                                                                                                                                                     
  0                                                                    34.1                                              33.8                                                   35.1                                              35.1                                                         31.1                                              30.1
  1                                                                    65.7                                              65.2                                                   64.3                                              64.9                                                         68.9                                              69.9
  Smoking status (%)                                                                                                                                                                                                                                                                                                                             
  Current/former                                                       84.3                                              85.6                                                   96.8                                              87.4                                                         77.7                                              78.0
  Never                                                                14.1                                              12.8                                                   3.2                                               12.6                                                         22.3                                              22.0
  Unknown                                                              1.5                                               1.5                                                    0                                                 0                                                            0                                                 0
  Histologic type (%)                                                                                                                                                                                                                                                                                                                            
  Squamous                                                             29.5                                              29.2                                                   18.8                                              17.9                                                         38.1                                              39.1
  Non‐squamous                                                         70.5                                              70.8                                                   81.2                                              82.1                                                         61.9                                              60.9
  PD‐L1 TPS (%)                                                                                                                                                                                                                                                                                                                                  
  ≥1                                                                   100.0                                             100.0                                                  100.0                                             100.0                                                        100.0                                             100.0
  1‐49                                                                 48.2                                              51.6                                                   0                                                 0                                                            53.1                                              52.9
  ≥50                                                                  51.8                                              48.4                                                   100.0                                             100.0                                                        46.9                                              47.1
  PD‐L1 expression assay[^b^](#ctm214-tbl1-note-0003){ref-type="fn"}   28‐8 pharmDx                                      22C3 pharmDx                                           22C3 pharmDx                                                                                                                                                     
  Interventions                                                        N‐I[^c^](#ctm214-tbl1-note-0004){ref-type="fn"}   AP or GP[^d^](#ctm214-tbl1-note-0005){ref-type="fn"}   PEM[^e^](#ctm214-tbl1-note-0006){ref-type="fn"}   AP or GP or TP[^f^](#ctm214-tbl1-note-0007){ref-type="fn"}   PEM[^e^](#ctm214-tbl1-note-0006){ref-type="fn"}   AP or TP[^g^](#ctm214-tbl1-note-0008){ref-type="fn"}
  Endpoints                                                                                                                                                                                                                                                                                                                                      
  Follow‐up time (mo)                                                  29.3                                              25.2                                                   12.8                                                                                                                                                             
  PD‐L1 ≥ 1%                                                                                                                                                                                                                                                                                                                                     
  OS (mo), HR (95% CI)                                                 17.1 vs 14.9, 0.79 (0.65‐0.96)                                                                                                                             16.7 vs 12.1, 0.81 (0.71‐0.93)                                                                                 
  PFS (mo), HR (95% CI)                                                5.1 vs 5.6, 0.82 (0.69‐0.97)                                                                                                                               5.4 vs 6.5, 1.07 (0.94‐1.21)                                                                                   
  ORR (%)                                                              36 vs 30                                                                                                                                                   27 vs 27                                                                                                       
  mDOR (mo)                                                            23.2 vs 6.2                                                                                                                                                20.2 vs 8.3                                                                                                    
  PD‐L1 = 1‐49%                                                                                                                                                                                                                                                                                                                                  
  OS (mo), HR (95% CI)                                                 15.1 vs 15.1, 0.94 (0.75‐1.18)                                                                                                                             13.4 vs 12.1, 0.92 (0.77‐1.11)                                                                                 
  PD‐L1 ≥ 50%                                                                                                                                                                                                                                                                                                                                    
  OS (mo), HR (95% CI)                                                 21.2 vs 14.0, 0.70 (0.55‐0.90)                    30.0 vs 14.2, 0.63 (0.47‐0.86)                         16.7 vs 12.1, 0.69 (0.56‐0.85)                                                                                                                                   
  PFS (mo), HR (95% CI)                                                6.7 vs 5.6, 0.62 (0.49‐0.79)                      10.3 vs 6.0, 0.50 (0.37‐0.68)                          7.1 vs 6.4, 0.81 (0.67‐0.99)                                                                                                                                     
  ORR (%)                                                              44 vs 35                                          45 vs 28                                               39 vs 32                                                                                                                                                         
  mDOR (mo)                                                            31.8 vs 5.8                                       NR vs 6.3                                              20.2 vs 10.8                                                                                                                                                     

Abbreviations: PD‐L1 TPS, PD‐L1 tumor proportion score; N‐I, nivolumab + ipilimumab; PEM, pembrolizumab; OR, overall survival; PFS, progression‐free survival; ORR, objective response rate; mDOR, median duration of response; 95% CI, 95% confidence interval (CI); mo, months.

Performance‐status evaluation of the Eastern Cooperative Oncology Group.

PD‐L1 expression status was determined using PD‐L1 IHC 28‐8 pharmDx assay (Code SK005) and PD‐L1 IHC 22C3 pharmDx assay (Dako North America).

Nivolumab (3 mg/kg Q2W) + ipilimumab (1 mg/Q6W).

AP: pemetrexed (500 mg/m2 Q3W) + cisplatin (75 mg/m2 Q3W)/carboplatin (AUC = 5‐6 Q3W); GP: gemcitabine (1000 or 1250/m2) + cisplatin (75 mg/m2) or gemcitabine (1000 mg/m2) + carboplatin (AUC = 5 Q3W).

Pembrolizumab 200 mg Q3W.

AP: pemetrexed (500 mg/m2 Q3W) + cisplatin (75 mg/m2 Q3W)/carboplatin (AUC = 5‐6 Q3W); GP: gemcitabine (1250 mg/m2 Q3W) + cisplatin (75 mg/m2 Q3W)/carboplatin (AUC = 5‐6 Q3W); TP: paclitaxel (200 mg/m2 Q3W) + carboplatin (AUC = 5‐6 Q3W).

AP: pemetrexed (500 mg/m2 Q3W) + carboplatin (AUC = 5‐6 Q3W); TP: paclitaxel (200 mg/m2 Q3W) + carboplatin (AUC = 5‐6 Q3W).

John Wiley & Sons, Ltd.

3.2. Direct comparisons of N‐I/PEM versus chemotherapy {#ctm214-sec-0110}
------------------------------------------------------

For patients with tumor PD‐L1 level of 1% or greater, those receiving N‐I experienced improved PFS (HR~N‐I/chemo~ 0.82, 95% CI 0.69‐0.97) and OS (HR~N‐I/chemo~ 0.79, 95% CI 0.65‐0.96) compared with those receiving chemotherapy (Table [1](#ctm214-tbl-0001){ref-type="table"}). Similar OS improvement was observed with PEM relative to chemotherapy (HR~PEM/chemo~ 0.81, 95% CI 0.71‐0.93). However, PEM did not result in clear PFS benefit compared with chemotherapy (HR~PEM/chemo~ 1.07, 95% CI 0.94‐1.21). Neither N‐I (RR~N‐I/chemo~ 1.20, 95% CI 0.98‐1.46) nor PEM (RR~PEM/chemo~ 1.03, 95% CI 0.86‐1.23) were associated with improved response rate.

Further direct analyses of benefit according to PD‐L1 level are as follows (Figure [2](#ctm214-fig-0002){ref-type="fig"} and Table [2](#ctm214-tbl-0002){ref-type="table"}): ≥50%, HR~N‐I/chemo~ for death 0.70, 95% CI 0.55‐0.90; HR~PEM/chemo~ for death 0.67, 95% CI 0.56‐0.80; HR~N‐I/chemo~ for disease progression or death 0.62, 95% CI 0.49‐0.79; HR~PEM/chemo~ for disease progression or death 0.70, 95% CI 0.60‐0.83; RR~N‐I/chemo~ for response 1.16, 95% CI 0.91‐1.47; RR~PEM/chemo~ for response 1.35, 95% CI 1.13‐1.61.1‐49% (only OS data available), HR~N‐I/chemo~ for death 0.94, 95% CI 0.75‐1.18; HR~PEM/chemo~ for death 0.92, 95% CI 0.77‐1.11.\<1% (only N‐I has data), HR~N‐I/chemo~ for death 0.62, 95% CI 0.48‐0.78.

![Direct comparisons between pembrolizumab (PEM) with chemotherapy (Chemo) for patients with PD‐L1 level greater than 50%. A‐C, Forest plot of hazard ratios (HRs) and risk ratio (RR) comparing overall survival (OS) (A), progression‐free survival (PFS) (B), and objective response rate (ORR) (C) between PEM with Chemo. The size of the data markers (squares) corresponds to the weight of the study in the meta‐analysis. The horizontal line crossing the square represents the 95% CI. The diamonds represent the estimated overall effect based on the meta‐analysis](CTM2-10-107-g002){#ctm214-fig-0002}

###### 

Summary of clinical outcomes according to PD‐L1 expression level

  Subgroup          N‐I versus chemo   PEM versus chemo    N‐I versus PEM
  ----------------- ------------------ ------------------- ------------------
  PD‐L1 ≥ 1%                                               
  OS HR (95% CI)    0.79 (0.65‐0.96)   0.81 (0.71‐0.93)    0.98 (0.77‐1.24)
  PFS HR (95% CI)   0.82 (0.69‐0.97)   1.07 (0.94‐1.21)    0.77 (0.62‐0.95)
  ORR RR (95% CI)   1.20 (0.98‐1.46)   1.03 (0.86‐1.23)    1.17 (0.89‐1.52)
  PD‐L1 = 1‐49%                                            
  OS HR (95% CI)    0.94 (0.75‐1.18)   0.92 (0.77‐1.11)    1.02 (0.76‐1.37)
  PD‐L1 ≥ 50%                                              
  OS HR (95% CI)    0.70 (0.55‐0.90)   0.63 (0.47‐0.86)    1.04 (0.77‐1.42)
  PFS HR (95% CI)   0.62 (0.49‐0.79)   0.50 (0.37‐0.68)    0.88 (0.66‐1.18)
  ORR RR (95% CI)   1.16 (0.91‐1.47)   1.35 (1.13‐1.61)    0.86 (0.64‐1.16)
  PD‐L1 \< 1%                                              
  OS HR (95% CI)    0.62 (0.48‐0.78)   No available data   

Abbreviations: PD‐L1 TPS, programmed cell death‐ligand 1 tumor proportion score; N‐I, nivolumab + ipilimumab; PEM, pembrolizumab; chemo, chemotherapy; HR, hazard ratio; 95% CI, 95% confidence interval.

John Wiley & Sons, Ltd.

3.3. Indirect comparisons between N‐I versus PEM of efficacy and safety {#ctm214-sec-0120}
-----------------------------------------------------------------------

Results from indirect comparisons showed that N‐I was statistically associated with longer PFS than PEM (HR~N‐I/PEM~ 0.77, 95% CI 0.62‐0.95). However, N‐I was not superior to PEM in terms of OS (HR~N‐I/PEM~ 0.98, 95% CI 0.77‐1.24) and ORR (RR~N‐I/PEM~ 1.17, 95% CI 0.89‐1.52) (Figure [3A](#ctm214-fig-0003){ref-type="fig"}). In subgroup analyses, OS was comparable between N‐I and PEM in pre‐specified subgroups including PD‐L1 level, gender, smoking status, Eastern Cooperative Oncology Group performance status (PS), and histology (Figure [3B](#ctm214-fig-0003){ref-type="fig"}). Nevertheless, there was a trend toward improved OS with N‐I versus PEM in younger patients (\<65 years: HR~N‐I/PEM~ 0.86, 95% CI 0.64‐1.17) and patients of good PS (PS 0: HR~N‐I/PEM~ 0.86, 95% CI 0.56‐1.31).

![Indirect comparisons of efficacy and safety between nivolumab plus ipilimumab (N‐I) versus pembrolizumab (PEM) for patients with positive programmed cell death‐ligand 1 (PD‐L1) expression. A, Results of indirect analysis for overall survival (OS), progression‐free survival (PFS) and objective response rate (ORR) between N‐I and PEM. The solid lines represent the existence of direct comparisons between the treatments, whereas the dashed line represents the indirect comparison between N‐I versus PEM. The size of the circle corresponds to the number of enrolled patients. B, Forest plot of hazard ratios (HRs) for OS in all subgroups between N‐I and PEM. *P‐*value with a marker^a^ demonstrates the significance of differences between the subgroups. C, Forest plot of risk ratios (RRs) for treatment‐related adverse events (TRAEs) between N‐I and PEM. The horizontal line crossing the square represents the 95% confidence interval (CI) in (B) and (C). The diamonds represent the estimated overall effect based on the meta‐analysis. All statistical tests were two‐sided. Abbreviations: chemo, chemotherapy](CTM2-10-107-g003){#ctm214-fig-0003}

Analyses of TRAEs suggested a less‐favorable toxicity profile with N‐I relative to PEM (Figure [3C](#ctm214-fig-0003){ref-type="fig"}). The rate of all grades (RR 1.28, 95% CI 1.17‐1.40) and ≥grade 3 (RR 2.18, 95% CI 1.7‐2.8) TRAEs were both significantly higher with N‐I compared with PEM. The rate of TRAEs leading to drug discontinuation occurred more frequently in those receiving N‐I (RR 3.08, 95% CI 1.81‐5.23). Treatment‐related deaths were similar between N‐I and PEM (RR 1.24, 95% CI 0.30‐5.11). Risks of some commonly reported TRAEs are presented in Table [3](#ctm214-tbl-0003){ref-type="table"}.

###### 

Relative risks for treatment‐related adverse events with N‐I versus PEM

                                           Relative risk for N‐I versus PEM                        
  ---------------------------- ----------- ---------------------------------- -------------------- -------
  Rash                         Any grade   1.91                               1.00‐3.62 (.049)     0.328
                               Grade ≥ 3   2.78                               0.05‐168.18 (.625)   2.093
  Diarrhea                     Any grade   2.33                               1.41‐3.87 (.001)     0.259
                               Grade ≥ 3   0.83                               0.11‐6.41 (.862)     1.041
  Pruritus                     Any grade   5.17                               1.63‐16.39 (.005)    0.588
                               Grade ≥ 3   1.02                               0.01‐74.71 (.992)    2.189
  Fatigue                      Any grade   1.70                               1.12‐2.58 (.013)     0.213
                               Grade ≥ 3   5.31                               1.10‐25.56 (.037)    0.802
  Decreased appetite           Any grade   2.04                               1.31‐3.16 (.002)     0.224
                               Grade ≥ 3   2.51                               0.46‐13.67 (.288)    0.865
  Asthenia                     Any grade   2.01                               1.10‐3.68 (.023)     0.308
                               Grade ≥ 3   4.27                               0.68‐26.7 (.121)     0.936
  Nausea                       Any grade   1.60                               1.04‐2.47 (.032)     0.22
                               Grade ≥ 3   3.22                               0.24‐42.85 (.377)    1.321
  Vomiting                     Any grade   2.36                               1.18‐4.7 (.015)      0.352
                               Grade ≥ 3   0.24                               0.01‐3.88 (.314)     1.424
  Constipation                 Any grade   1.80                               0.83‐3.89 (.135)     0.394
                               Grade ≥ 3                                                           
  Anemia                       Any grade   0.79                               0.43‐1.45 (.445)     0.313
                               Grade ≥ 3   1.95                               0.59‐6.44 (.272)     0.609
  Neutrophil count decreased   Any grade   3.57                               0.74‐17.29 (.115)    0.805
                               Grade ≥ 3   1.13                               0.03‐36.79 (.947)    1.779
  Neutropenia                  Any grade   0.31                               0.04‐2.65 (.286)     1.09
                               Grade ≥ 3   0.68                               0.03‐16.77 (.815)    1.634

Abbreviations: N‐I, nivolumab plus ipilimumab; PEM, pembrolizumab.

John Wiley & Sons, Ltd.

4. DISCUSSION {#ctm214-sec-0130}
=============

To the best of our knowledge, this is the first study to compare the efficacy and safety between N‐I and PEM in NSCLC, via indirect comparison. This hypothesis‐generating study revealed that nivolumab plus low‐dose, long‐interval ipilimumab had superior PFS over PEM as 1L treatment for patients with PD‐L1‐positive advanced NSCLC. However, this benefit was absent in terms of OS (across different subgroups) and ORR. Overall, patients receiving N‐I experienced more TRAEs than those receiving PEM.

The KEYNOTE‐042 was the pivotal study showing that PEM outperformed chemotherapy as 1L treatment of PD‐L1‐positive advanced NSCLC. However, exploratory analysis implied that PEM provided long‐term survival to only those with PD‐L1 TPS of ≥50% but not those between 1% and 49%. Furthermore, the CheckMate 026 study showed that neither PFS nor OS were prolonged with nivolumab in patients with \>5% tumor PD‐L1 staining.[^8^](#ctm214-bib-0008){ref-type="ref"} These data implied that monotherapy blockade of PD‐1 failed to provide benefit for a broader population of patients. One explanation is that PD‐1/PD‐L1 engagement is not the only mediator for immune evasion of tumor cells. Among this process, CTLA‐4 plays an important role in the early‐phase regulation of T‐cell proliferation, whereas PD‐1 participates in the latter phase. This complementary mechanism of action makes the dual inhibition of CTLA‐4 and PD‐1 an appealing approach,[^9^](#ctm214-bib-0009){ref-type="ref"} which has been clinically proved in melanoma[^10^](#ctm214-bib-0010){ref-type="ref"} and renal cell carcinoma.[^11^](#ctm214-bib-0011){ref-type="ref"}

Unexpectedly, our analysis showed comparable efficacy between N‐I and PEM in NSCLC except that the latter one was associated with longer PFS. The rationale for the absence of OS benefits remains to be unveiled. Possible explanations may include insufficient synergy of dual inhibition of CTLA‐4 and PD‐1 in NSCLC, limited efficacy of CTLA‐4 blockade in NSCLC, inappropriate dosing and interval of ipilimumab, lack of established predictive biomarkers (given that both PD‐L1 and tumor mutation burden failed), unbalanced post‐progression treatment, and unequal performance of chemotherapy arms across different studies. An ongoing phase III study is evaluating PEM plus ipilimumab versus PEM in NSCLC patients with PD‐L1 TPS of ≥50% (KEYNOTE‐598, NCT03302234), which will further provide answers for whether there is an added value of ipilimumab to PD‐1 blockade and whether there is a difference between nivolumab and PEM, when combined with ipilimumab.

Noteworthy, exploratory analysis indicates that N‐I improves OS in patients with PD‐L1‐negative NSCLC. This is clinically relevant because chemotherapy is currently unavoidable in this subset of patients. Additionally, in our subgroup analyses, a trend toward improved OS was observed in younger patients and in patients with good performance status who were receiving N‐I therapy, which required further investigation. With increasing studies exploring the frontline immunotherapy of NSCLC, there will be growing challenges to determine which treatment is best for patients with different clinicopathological characteristics: chemotherapy plus immunotherapy, immunotherapy alone, immunotherapy plus immunotherapy, or immunotherapy plus anything else.

Several limitations should be considered. First, this is an integrated analysis of published results rather than individual patient\'s data. Second, we lack head‐to‐head comparisons. In addition, only three qualified trials were included. Therefore, the interpretation of the results needs additional caution. Considering these limitations, head‐to‐head randomized trials will be required to directly compare PEM against N‐I.

In conclusion, our study indicates that N‐I and PEM provide comparable overall survival benefit for PD‐L1‐positive NSCLC, though mostly driven by the group of PD‐L1 ≥ 50%. N‐I was associated with superior PFS relative to PEM but at meaningful cost of toxicities. Both regimens spare patients from 1L chemotherapy and change the practice paradigm of NSCLC. Clinicians should carefully balance the efficacy, toxicity, and costs of different regimens in order to optimize clinical outcomes.
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